PurposeThis study determined the seroprevalence of herpes virus 2 in gravidas and the differences between herpes virus 2-infected and healthy gravidas. The need to screen gravidas for herpes virus 2 was also evaluated.Materials and MethodsA retrospective analysis involving 500 gravidas who underwent herpes virus 2 serologic testing and delivery in our hospital between January 2009 and August 2010 was performed. All patients in the study group were classified as herpes simplex virus 2 (HSV2) positive, and all cases were analyzed with respect to the clinical course of the pregnancy, pregnancy outcome, obstetric complications, and neonatal outcomes. SPSS software (version 14.0) was used for statistical analysis. A chi-square test and Student's t-test were used for statistical analysis.ResultsIn the current study, the herpes virus 2 seroprevalence rate in gravidas was 17%. There was no significant difference in the rates of preterm delivery, premature rupture of membranes, preterm labor, and intrauterine growth restriction between the herpes virus 2-infected gravidas and the healthy control group. The rates of spontaneous abortion and sexually transmitted disease were higher in the herpes virus 2 infection group than the healthy control group.ConclusionAfter educating gravidas on genital herpes and, if gravidas thereafter consent to herpes virus 2 screening, the risk of neonatal herpes virus 2 infections can be reduced. In addition, examination of gravidas for sexually transmitted diseases would increase as would appropriate treatment.
ObjectiveThe purpose of this study was to evaluate the correlation between complement (C3 and C4) levels, anti-dsDNA titers, autoimmune target test (AITT), and pregnancy complications.
MethodsNinety-three pregnancies with systemic lupus erythematosus (SLE) were analyzed retrospectively. We evaluated the course of the pregnancy and outcome, pregnancy complications, progression of SLE, maternal complications of SLE, drugs taken before and after pregnancy, neonatal outcomes, and C3/C4 levels, anti-dsDNA titers, and AITT results. SPSS ver. 14.0 was used for statistical analysis. The average and standard deviation are shown. Chi-square test and Pearson correlation test were used for statistical analysis. The significance level was set at 0.05.
ResultsThe C3 level was associated with maternal leukopenia, elevated serum C-reactive protein (CRP) elevation, hematuria, hypertension, and preterm premature rupture of membranes. The C4 level was associated with maternal proteinuria, hematuria, hematologic disease, and admission to the neonatal intensive care unit. The anti-dsDNA titer was associated with elevated maternal serum CRP, oligohydramnios, and neonatal anti-Sjögren's syndrome B (La) antibody. The AITT result was related to elevated erythrocyte sedimentation rate, and 1 and 5 minute Apgar scores.
ConclusionOur result show that adding the AITT to conventional C3/C4 and anti-dsDNA testing in gravidas with SLE might help antenatal care.
A sclerosing stromal tumor of the ovary is an extremely rare benign tumor in pregnant women. Only 9 reports of sclerosing stromal tumor of the ovary during pregnancy have been presented. A 26-year-old woman at the 10th week of gestation was explored via laparoscopic surgery. She had non-specifi c symptoms but high levels of the tumor marker. The pathological diagnosis was sclerosing stromal tumor of the right ovary. We report a case of sclerosing stromal tumor in a 26-year-old woman who was admitted to confi rm pregnancy with a review of the literature.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.